Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
By Dr. Matthew Watson
COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 3, 2020. Company executives will provide a business overview and update on the company’s pipeline programs.
Read this article:
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
Arvinas to Participate in Upcoming Virtual Investor Conferences
By Dr. Matthew Watson
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences:
Read the original post:
Arvinas to Participate in Upcoming Virtual Investor Conferences
AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020
By Dr. Matthew Watson
SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. With a strong fourth quarter already underway, the Company forecasts a revenue growth of approximately 100% in 2020 over 2019, with a revenue range of US$3 million (~ RMB20 million) to US$3.3 million (~ RMB22 million). For 2019, the Company had a revenue of US$1.6 million (~ RMB10.9 million) (using a current US$ to RMB exchange ratio of ~ 6.6). We expect the strong momentum of YoY revenue growth due to market demand and customers accepting AnPac Bio’s novel cancer screening technology with multiple advantages (named cancer differentiation analysis (CDA) technology)) to continue into 2021. The Company plans to release its full year 2020 audited financial report in early March 2021.
More:
AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020
Radient Technologies Announces partnership with US based Dreamy CBD
By Dr. Matthew Watson
EDMONTON, Alberta, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), is pleased to announce a licensing agreement with Dreamy Co., (“Dreamy”) to bring in Dreamy CBD products under Radient’s platform to Canada and extend it to other international markets. Initially founded in the US, Dreamy has developed a lifestyle brand over the past decade focused on the Health and Wellness space before branching into the CBD vertical. Dreamy is focused on creating and inspiring people to use plant medicine and holistic healing in place of conventional pharmaceutical solutions. In the US, Dreamy CBD enjoys a strong presence in California, and the Dreamy brand has a strong association with a positive lifestyle in the rapidly growing Wellness space. The Dreamy CBD products comprise CBD tinctures, CBD distillates, CBD edibles, CBD cosmetics, and CBD Vape Cartridges geared towards the recreational and medical cannabis market.
See the original post here:
Radient Technologies Announces partnership with US based Dreamy CBD
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
By Dr. Matthew Watson
MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd today announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) technology to develop novel immunotherapies for a range of cancers and infectious diseases.
Equillium Provides Itolizumab COVID-19 Program Update
By Dr. Matthew Watson
Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020
Here is the original post:
Equillium Provides Itolizumab COVID-19 Program Update
Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit…
By Dr. Matthew Watson
See the rest here:
Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit...
Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) – 3 years ISO 9001-2015 certification successfully obtained
By Dr. Matthew Watson
Loos, France, Isovital Headquarter, Nov 24th 2020 - Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) - 3 years ISO 9001-2015 certification successfully obtained for the “National, international distribution and logistics of cooled pharmaceutical, biological, diagnostic and radioactive products”.
View original post here:
Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) - 3 years ISO 9001-2015 certification successfully obtained
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
By Dr. Matthew Watson
WOBURN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders. The advisors join as the Company continues development of its neutralizing antibody therapeutic, ABP300, in clinical trials for treatment of SARS-CoV2 (COVID-19) infection.
Visit link:
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference
By Dr. Matthew Watson
FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.
See the original post here:
Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference
GBT Announces Participation in Upcoming Investor Conferences
By Dr. Matthew Watson
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:
See more here:
GBT Announces Participation in Upcoming Investor Conferences
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
By Dr. Matthew Watson
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president, and Elizabeth Trehu, M.D., chief medical officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
Read more from the original source:
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference
By Dr. Matthew Watson
BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.
Read more:
VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference
AgraFlora Organics Receives Analytical Equipment for its Winnipeg Edibles Manufacturing Facility
By Dr. Matthew Watson
VANCOUVER, British Columbia, Nov. 25, 2020 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that it has acquired High Performance Liquid Chromatography (“HPLC”) equipment for AgraFlora’s 51,000-Square-foot fully-automated edibles manufacturing facility in Winnipeg, Manitoba (the “Edibles Facility”).
See the article here:
AgraFlora Organics Receives Analytical Equipment for its Winnipeg Edibles Manufacturing Facility
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
By Dr. Matthew Watson
Scheduled to Reconvene on December 16, 2020Company Urgently Encourages Stockholders to Vote
See original here:
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
By Dr. Matthew Watson
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020. Aquestive will host one-on-one investor meetings on December 2, 2020.
Read the original:
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
By Dr. Matthew Watson
PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 and host investor meetings.
See the rest here:
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S
By Dr. Matthew Watson
Company announcement no. 29/2020
See the article here:
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S
Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg
By Dr. Matthew Watson
EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas announced the retirement of Ivan Lieberburg, MD, PhD from the Adamas board.
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
By Dr. Matthew Watson
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat at the Piper Sandler 32nd Annual Healthcare Conference, being held December 1-3, 2020.
Read the original post:
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference